Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Pall Corporation Acquires Molecular Diagnostics Manufacturer GeneSystems

By LabMedica International staff writers
Posted on 03 Oct 2008
Pall Corp. More...
(East Hill, NY, USA), a global leader in filtration, separation, and purification, has purchased GeneSystems (Bruz, France), a privately held biotechnology company that has developed a unique, easy-to-use, and cost-effective molecular diagnostics platform.

The acquisition of GeneSystems with its patented approach to rapid microbiologic detection equipment and disposables expands Pall's total fluid management (TFM) capabilities in the US$1 billion biopharmaceuticals process monitoring market. The acquisition also presents Pall with new opportunities in its environmental, food, and beverage and water markets.

Process monitoring includes the analytic tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing, and finished product release testing. These tests are receiving increased regulatory scrutiny and support under initiatives such as process analytic technology (PAT).

Founded in 2000, GeneSystems quickly gained market recognition for its quantitative Legionella diagnostic platform. Since its first product arrived on the market in 2004, GeneSystems has developed systems for the rapid and precise diagnosis of a range of pathogens, including food safety testing focused on Escherichia coli. These systems employ advanced sample preparation methods and real-time polymerase chain reaction (PCR) technology to enable fast and high throughput along with high reproducibility analysis of multiple DNA targets. Real-time PCR detects small quantities of specific microorganisms and provides results within hours.

"We are excited by this acquisition and the increased opportunities it presents for our pharmaceutical, biotechnology, environmental monitoring, quality control, and diagnostics programs,” said Eric Krasnoff, Pall Corporation chairman and CEO. "Customers seek better tools for rapid testing and process monitoring. GeneSystems expands our ability to provide total fluid management to meet customer's raw materials, production, testing, and environmental requirements. GeneSystems' unique technologies complement Pall's markets and global reach.”

"It is wonderful to join Pall and have the opportunity to expand on a global scale the very significant customer advantages that our team has achieved, diligently and creatively, during the last few years,” said Darryl Spurling, CEO of GeneSystems.

Pall Corp. is a global leader in the rapidly growing field of filtration, separation, and purification. Pall is organized into two businesses: life sciences and industrial. These businesses provide products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation, and broad industrial markets. The company has extensive operations around worldwide.

Related Links:
Pall Corp
GeneSystems


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.